An Idiots Guide to Statistics Curriculum 3.6 - PowerPoint PPT Presentation

1 / 50
About This Presentation
Title:

An Idiots Guide to Statistics Curriculum 3.6

Description:

An Idiots Guide to Statistics Curriculum 3.6 Daisy de Ferranti Stephanie de Giorgio Lindo Van der Merwe Overview Why bore you with Statistics Definitions How to work ... – PowerPoint PPT presentation

Number of Views:131
Avg rating:3.0/5.0
Slides: 51
Provided by: DaisyFe2
Category:

less

Transcript and Presenter's Notes

Title: An Idiots Guide to Statistics Curriculum 3.6


1
An Idiots Guide to StatisticsCurriculum 3.6
  • Daisy de Ferranti
  • Stephanie de Giorgio
  • Lindo Van der Merwe

2
(No Transcript)
3
Overview
  • Why bore you with Statistics
  • Definitions
  • How to work through the stats questions

4
Why bore you with Statistics
  • AKT- Definitions, interpretation of terms, 2 by 2
    table (and forest plot for statisticians!)

5
Present Absent
Positive a b
Negative c d
6
Present Absent
Positive True positive False positive
Negative False negative True negative
7
Definitions
  • Sensitivity (True positive rate) How good is
    this test at picking up people who have the
    condition?
  • a/ac

8
Specificity
  • True negative rate
  • How good is this test at correctly excuding
    people without the condition
  • d/bd

9
Positive Predictive value
  • Post test probability of a positive test
  • If a person tests positive, what is the
    probability that he has the condition
  • a/ab

10
Negative predictive value
  • Post test probability of a negative test
  • If a person tests negative what is the probabilty
    that he does not have the condition
  • d/cd

11
How to remember this!
  • SnNOUT with high sensitivity a negative result
    rules OUT the diagnosis
  • SpPin with high specificity, a positive result
    rules IN the diagnosis

12
An example
Gastric cancer Gastric cancer Gastric cancer Gastric cancer
Blood result Present Absent
Blood result Positive 20 30
Blood result Negative 5 45
13
  • Sensitivity
  • 20/25 0.8
  • Specificity
  • 45/75 0.6
  • PPV
  • 20/50 0.4
  • NPV
  • 45/50 0.9

14
Accuracy
  • What proportion of all tests have given the
    correct result (ie true positives and true
    negatives as a proportion of all the results)
  • ad/abcd

15
Likelihood ratio of a positive test
  • How much more likely is positive test to be found
    in a person with, as opposed to without, the
    condition
  • Sensitivity/1-specificity

16
Interventions
Dead Alive Total no
Control 404 a 921 b 1324 ab
Surgical 350 c 974 d 1325 cd
17
Risk
  • Chance of being dead in control group
  • X
  • Chance of being dead in surgical group
  • Y

18
Relative Risk
  • RR of death is the risk in surgical pts compared
    with controls.
  • y/x

19
Relative risk reduction
  • Amount by which the risk of death is reduced by
    surgery

20
Another practical example treatment of candida
Improved Not improved Total no
Antifungal 80 20 100
Placebo 60 40 100
21
  • Risk in placebo group 40/1000.440
  • Risk in treatment group 20/1000.220
  • Absolute risk reduction (ARR)
  • 80/100 60/100 20
  • Relative risk reduction
  • Risk in placebo (40) risk in treatment(20)
    0.5
  • Risk in placebo (40)

22
Glossary Index
23
Hierarchy of Evidence
  • Systematic review meta-analysis
  • RCT
  • Cohort studies
  • Case-control studies
  • Cross-sectional surveys
  • Case reports

24
Types of Study
  • Case control
  • Retrospective
  • Group of cases with condition group of controls
    without are studied to determine relative
    frequency of particular exposures of interest in
    2 groups
  • Concerned with aetiology of disease rather than
    Rx
  • Cohort
  • Prospective
  • Two groups of people are selected on basis of
    differences in their exposure to particular agent
    followed up to establish how many in each group
    develop a particular disease
  • Follow up period generally years
  • Concerned with aetiology of disease

25
Types of Study
  • 1. Case reports
  • Describes medical hx of single pt in form of
    story.
  • 2. Cross-sectional surveys
  • Population or sample of population examined to
    determine prevalence of certain condition

26
Types of Study
  • 5. RCT
  • Participants in trial are randomly allocated to
    either one intervention (ie drug) or another (ie
    placebo)
  • Both groups followed up for specified time
    analysed in terms of specific outcomes defined at
    onset (ie death, MI)
  • Often short follow up due to costs pressure to
    produce timely evidence
  • 6. Systematic Reviews Meta-analysis
  • Systematic review Summary of medical literature
    that uses explicit methods to perform a thorough
    search critical appraisal of individual studies
  • Meta-analysis A systematic review that uses
    quantitative methods to summarise results
    pooling all information from number of different
    (but similar) studies

27
Statistics which describe Data
  • Mean
  • Median
  • Mode
  • Standard Deviation

28
  • Mean
  • Sum of all values, divided by the number of
    values
  • Used in normal distribution spread of data is
    fairly similar on each side of mid point

29
  • Median
  • It is the point which has half the values above
    half below
  • Used to represent average when data not
    symmetrical - skewed distribution
  • Meanmedian in symmetrical distribution but not
    in skew distribution
  • Mode
  • Most common set of events

30
  • Standard
    Deviation
  • Good news not necessary to know how to
    calculate the SD!
  • Used for data which is normally distributed
  • SD indicates how much a set of values is spread
    around the mean
  • /- 1 SD (range of one SD above below the mean)
    includes 68.2 of the values
  • /- 2 SD includes 95.4 of values
  • /- 3 SD includes 99.7

31
Statistics which test confidence
  • P value
  • Confidence interval

32
P value
  • Test of probability ie any observed difference
    having happened by chance
  • Used to determine whether a hypothesis is true
  • Null hypothesis no difference between two
    groups/treatments
  • P value lt0.05 statistically significant ie
    unlikely to have happened by chance, hence
    important
  • The lower the p value, the less likely the
    difference happened by chance thus the higher
    the significance
  • Significant p rejects Null hypothesis

33
Confidence interval
  • When is it used?
  • Typically when, instead of simply wanting mean
    value of sample, we want a range that is likely
    to contain the true population value
  • True value is mean value that we would get if
    we had data for the whole population
  • What does it mean?
  • CI gives the range in which the true value is
    likely to be (usually with level of 95
    certainty)
  • Provides same information as p value, but more
    useful
  • Size of CI related to sample size of study
    larger studies have narrower CI
  • If CI crosses 0 Null hypothesis true

34
Forest Plot/blobbogram
35
Forest Plot
  • Allows readers to see information from individual
    studies that went into the meta-analysis at a
    glance
  • Results of component studies are shown as squares
    centred on point estimate of result of each study
  • Horizontal line runs through to show its CI
  • Diamond symbol represents the overall estimate
    from meta-analysis and its CI
  • Significance is achieved if the diamond is clear
    of the line of no effect

36
  • Interpretation
  • i. Wide CI, crosses 0
  • ii. Does not cross 0, intervention works but weak
    evidence
  • iii. Narrow CI, crosses 0, intervention no
    benefit
  • iv. Narrow CI, intervention works
  • v. Intervention detrimental
  • vi. Meta-analysis intervention works

37
Key definitions
  • Incidence proportion of a defined group
    developing a disease within a stated period
  • Prevalence proportion of a defined group having
    a disease at any one time
  • Single blinded subjects did not know which
    treatment they were receiving
  • Double blinded neither investigators nor
    subjects knew who was receiving which treatment
  • Unblinded all participants were aware of who
    received which intervention
  • Power ability of a study to minimise
    uncertainties that arise because of chance
    variation between samples - ie larger samples
  • Type II error common accept null when
    alternative is true
  • Type I error less common accept alternative
    when null is true

38
Enough of the theory heres the practical bit!!
  • What do we need to be able to do?
  • 1. Interpret drug rep data
  • 2. Explain risk/benefits to our patients
  • 3. Understand evidenced based medicine

39
Survival analysis and risk reduction
  • Use of ramipril in preventing stroke double
    blind randomised trial. BMJ 324699-702
  • To determine the effect of ramipril on secondary
    prevention of stroke.
  • 267 hospitals in 19 countries
  • 9297 patients with vascular disease or diabetes
    followed for 4.5 yrs (HOPE study)

40
  • Outcome stroke, TIA and cognitive function
    measured. Blood pressure recorded at entry to
    study, after 2 years and at end.
  • Results
  • Reduction in BP modest
  • Relative risk of stroke reduced by 31 in
    ramipril group compared to placebo, relative risk
    of fatal stroke reduced by 61

41
Summary of results
Stroke No-stroke Total
Ramipril 156 (Fatal 17) 4479 4635
Placebo 226 (Fatal 44) 4426 4652
42
  • Risk of stroke in ramipril group
  • 156/4635 0.036 3.36
  • Risk of stroke in placebo group
  • 226/4652 0.048 4.48
  • Relative risk reduction (4.86 3.36)/4.86
  • 0.31
  • 31

43
  • Absolute risk reduction (ARR)
  • Risk in placebo risk in rampril
  • 4.86 3.36 1.5
  • NNT 100 100 67
  • ARR 1.5

44
  • For fatal stroke
  • Risk in ramipril group 17/4635 0.0036
  • Risk in placebo group - 44/4652 0.0094
  • RRR 0.0094 - 0.0036 0.617 61
  • 0.0094

45
  • Rampril reduced risk of stroke in high risk
    patients by 31, which seems good.
  • However, have to treat 67 people for 4 ½ years in
    order to benefit 1 patient by preventing 1 stroke

46
Odds ratios and CI
  • Systematic r/v of long term anticoagulation or
    antiplatelet treatment in pts with atrial
    fibrillation BMJ 322321-326
  • Objective - to examine benefits/risks of warfarin
    compared to aspirin/indomethacin
  • Methods - meta-analysis of RCT. Odds ratios (95
    CI) calculated to estimate treatment effects

47
(No Transcript)
48
Results for one of the trials
Odds of vascular death in patients on
warfarin number of times an event happens
16 0.088 number of times it does not happen
197-16 Odds of vascular death in aspirin pts
14 0.080
188 - 14
Odds ratio odds in warfarin pts 0.088
1.10 odds in aspirin pts
0.080 Odds ratio of gt1 indicates that rate of
vasc death increased in warfarin pts over those
in aspirin pts.
49
  • If the confidence interval for the Odds Ratio
    containes 1 ie no difference, then the difference
    in results is NOT statistically significant
  • Seen by CI plot line crossing the line at 1.
  • Overall the study did not show any benefit of
    long term anticoagulation and an increased risk
    of bleeding

50
In summary
  • Important to understand for career, not just for
    exam.
  • Try to understand basic concepts well as can then
    apply to most questions.
Write a Comment
User Comments (0)
About PowerShow.com